

February 6, 2016

BSE Limited
Corporate Service Department
1st Floor, New Trading Ring
Rotunda Building, P.J. Tower
Dalal Street, Fort
Mumbai - 400 001

The National Stock Exchange of India Ltd.
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai – 400 051

Dear Sirs,

We enclose a copy of the Press Release being issued today.

This is for your kind information and records.

Thanking you,

Yours faithfully,
For Jubilant Life Sciences Limited


Rajiv Shah
Company Secretary



Encl: as above



Ministry of Commerce (MOFCOM) China has reduced the Anti-Dumping Duty on Pyridine from Jubilant to 17.6%

Noida (UP), India, Saturday, February 6, 2016

Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences Company, announced today that MOFCOM has reduced Anti-Dumping Duty on its Pyridine to 17.6% from existing 24.6% based on the review petition filed by the company.

The Company will continue to evaluate the market conditions and get the benefit of reduced duty going forward.

About Jubilant Life Sciences Limited

Jubilant Life Sciences Limited is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Specialty Pharmaceuticals and Life Science Ingredients. It also provides Services in Contract Manufacturing and Drug Discovery Solutions. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 12 world-class manufacturing facilities in India, US and Canada and a team of about 6,100 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.

For more information please contact:

For Investors

Ravi Agrawal / Anupam Jain
Jubilant Life Sciences Limited
Ph: +91-120 436 1002 / 1021
E-mail: ravi_agrawal@jubl.com
anupam_jain@jubl.com

Siddharth Rangnekar / Karl Kolah
Citigate Dewe Rogerson
Tel: +91 22 6645 1209 / 1220
E-mail: siddharth@cdr-india.com
karl@cdr-india.com

For Media

Sudhakar Safaya / Neha Garg
Jubilant Life Sciences Limited
Ph: +91-120 436 1034 / 1067
E-mail: sudhakar_safaya@jubl.com
neha_garg@jubl.com

Kanika Mittal
Perfect Relations
Ph: +91 9899574833
E-mail: kmittal@perfectrelations.com



Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.